|
1.
|
Peterson LB and Blagg BS: To fold or not
to fold: modulation and consequences of Hsp90 inhibition. Future
Med Chem. 1:267–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Porter JR, Fritz CC and Depew KM:
Discovery and development of Hsp90 inhibitors: a promising pathway
for cancer therapy. Curr Opin Chem Biol. 14:412–420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kim YS, Alarcon SV, Lee S, Lee MJ,
Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in
clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Massironi S, Sciola V, Peracchi M,
Ciafardini C, Spampatti MP and Conte D: Neuroendocrine tumors of
the gastro-enteropancreatic system. World J Gastroenterol.
14:5377–5384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Modlin IM, Oberg K, Chung DC, Jensen RT,
de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA,
Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P
and Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet
Oncol. 9:61–72. 2008. View Article : Google Scholar
|
|
7.
|
Janson ET, Sørbye H, Welin S, Federspiel
B, Grønbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A,
Thiis-Evensen E, Välimäki MJ, Oberg K and Knigge U: Nordic
Guidelines 2010 for diagnosis and treatment of
gastroenteropancreatic neuroendocrine tumours. Acta Oncol.
49:740–756. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Auernhammer CJ and Göke B: Therapeutic
strategies for advanced neuroendocrine carcinomas of jejunum/ileum
and pancreatic origin. Gut. 60:1009–1021. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008.
|
|
10.
|
Shah T, Hochhauser D, Frow R, Quaglia A,
Dhillon AP and Caplin ME: Epidermal growth factor receptor
expression and activation in neuroendocrine tumours. J
Neuroendocrinol. 18:355–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Zitzmann K, Rüden Jv, Brand S, Göke B,
Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of
Akt in response to mTOR and Raf inhibitors - a rationale for
dual-targeted therapy approaches in neuroendocrine tumor disease.
Cancer Lett. 295:100–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Gloesenkamp C, Nitzsche B, Lim AR, Normant
E, Vosburgh E, Schrader M, Ocker M, Scherübl H and Höpfner M: Heat
shock protein 90 is a promising target for effective growth
inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol.
40:1659–1667. 2012.PubMed/NCBI
|
|
13.
|
Gilbert JA, Adhikari LJ, Lloyd RV, Rubin
J, Haluska P, Carboni JM, Gottardis MM and Ames MM: Molecular
markers for novel therapies in neuroendocrine (carcinoid) tumors.
Endocr Relat Cancer. 17:623–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zitzmann K, de Toni E, von Rüden J, Brand
S, Göke B, Laubender RP and Auernhammer CJ: The novel Raf inhibitor
Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to
neuroendocrine tumour cells. Endocr Relat Cancer. 18:277–285. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Cakir M and Grossman A: The molecular
pathogenesis and management of bronchial carcinoids. Expert Opin
Ther Targets. 15:457–491. 2011.PubMed/NCBI
|
|
16.
|
Eccles SA, Massey A, Raynaud FI, Sharp SY,
Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall
F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K,
Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A,
Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B,
Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood
M, Wright L and Workman P: NVP-AUY922: a novel heat shock protein
90 inhibitor active against xenograft tumor growth, angiogenesis,
and metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Sharp SY, Prodromou C, Boxall K, Powers
MV, Holmes JL, Box G, Matthews TP, Cheung KM, Kalusa A, James K,
Hayes A, Hardcastle A, Dymock B, Brough PA, Barril X, Cansfield JE,
Wright L, Surgenor A, Foloppe N, Hubbard RE, Aherne W, Pearl L,
Jones K, McDonald E, Raynaud F, Eccles S, Drysdale M and Workman P:
Inhibition of the heat shock protein 90 molecular chaperone in
vitro and in vivo by novel, synthetic, potent resorcinylic
pyrazole/isoxazole amide analogues. Mol Cancer Ther. 6:1198–1211.
2007. View Article : Google Scholar
|
|
18.
|
Gaspar N, Sharp SY, Eccles SA, Gowan S,
Popov S, Jones C, Pearson A, Vassal G and Workman P: Mechanistic
evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and
pediatric glioblastoma. Mol Cancer Ther. 9:1219–1233. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Stühmer T, Zöllinger A, Siegmund D,
Chatterjee M, Grella E, Knop S, Kortüm M, Unzicker C, Jensen MR,
Quadt C, Chène P, Schoepfer J, García-Echeverría C, Einsele H,
Wajant H and Bargou RC: Signalling profile and antitumour activity
of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
Leukemia. 22:1604–1612. 2008.PubMed/NCBI
|
|
20.
|
Papouchado B, Erickson LA, Rohlinger AL,
Hobday TJ, Erlichman C, Ames MM and Lloyd RV: Epidermal growth
factor receptor and activated epidermal growth factor receptor
expression in gastrointestinal carcinoids and pancreatic endocrine
carcinomas. Mod Pathol. 18:1329–1335. 2005. View Article : Google Scholar
|
